选择性和强大的PROTAC降解c-Src激酶的降解剂
Wuxiang Mao1, Nathalie M Vandecan1, Christopher R Bingham1
1Department of Chemistry, University of Michigan, 930 N. University Avenue, Ann Arbor, Michigan 48109, United States.
ACS chemical biology
|December 19, 2023
概括
研究人员开发了新型的蛋白质分解向金马 (PROTACs),可以选择性地降解c-Src,这是一种涉及癌症的蛋白质激酶. 这种向降解为控制癌细胞增殖提供了与传统抑制相比显著的药理优势.
科学领域:
- 化学生物学 化学生物学
- 分子瘤学分子瘤学
- 药物发现 药物发现 药物发现
背景情况:
- Src家族的激酶,特别是c-Src,与各种癌症有关.
- 向c-Src是癌症治疗的一个有希望的策略.
- 传统的抑制可能有局限性;蛋白质降解提供了一个替代方案.
研究的目的:
- 开发用于c-Src降解的强大和有选择性的蛋白解向化马体 (PROTACs).
- 研究c-Src降解与抑制的药理优势.
- 探索特定c-Src形状在PROTAC设计中的作用.
主要方法:
- 设计和合成使用E3结合酶连接体的PROTACs.
- 采用对形状选择性连接体,针对c-Src的αC-螺旋外状态.
- 评估PROTAC的功效,选择性和催化效率.
- 对癌细胞扩散的评估,以应对c-Src降解.
主要成果:
- 鉴定一种强大且有选择性的双Csk/c-Src PROTAC降解剂.
- 开发一种高强度和选择性的c-Src PROTAC,使用一种选择性合体.
- 展示了开发的c-Src PROTACs的高催化效率.
- 在癌细胞增殖模型中,证据表明c-Src降解比抑制具有药理上的优势.
结论:
- 通过PROTACs向蛋白质降解是一种有效的c-Src策略.
- 形状选择性干增强了对c-Src.的PROTAC特异性和功效.
- 与癌症治疗的抑制相比,c-Src降解提供了优越的药理学益处.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Regulated Protein Degradation
7.3K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.3K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K


